Summary by Futu AI
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 40,000 shares of the company's Class A Common Stock on September 4 and 5, 2024. The transactions were executed at prices ranging from $6.04 to $6.14 per share, resulting in a total market value of $243,600. Following the sales, Gibson directly holds 762,656 shares of Recursion Pharmaceuticals.